Etiologically, gastroesophageal reflux disease (GERD) can be regarded as motility disorder. Although blocking acid is effective in the treatment of GERD, it does not overcome the underlying pathologic factors that allow acid, pepcin, and bile to rejfux into the esophagus. Prokinetic agents address the upper gastrointestinal motility disturbances contributing to GERD and, thus, have an important role in the short-and long-term medical management of reflux esophagitis. This paper discusses the rationalefor the effectiveness ofpharmacologic modulation by reviewing current concepts and postulated theories about the mechanisms underlying the neuromuscular abnormalities. The multifactorial aspects of GERD are addressed and the potential for tailoring medical therapy also emphasized.
ESOPHAGEAL MOTOR ACTIVITY IN REFLUX ESOPHAGITIS
Because acid is the major noxious agent in the refluxate material, the severity of esophagitis depends on the duration of time the esophagus is exposed to acid material. The esophageal acid exposure time or acid reflux time is a function of the frequency of reflux episodes, as well as the duration of each reflux episode. The frequency of reflux episodes is determined by the factors that impair the antireflux barrier. On the other hand, the ability to clear individual acid reflux episode and acid clearance time is determined by peristaltic activity of the esophagus and salivary neutralization capacity.
Helm et al. have contributed significantly to our understanding of the various factors that are important in the acid clearance times. The methodology uses the introduction of a small bolus of acid into the esophagus (usually 15 ml) and then asking the individual to swallow at 30 sec intervals. With the introduction of hydrochloric acid into the esophagus, the esophageal pH usually decreases to 1.2, and acid clearance time is usually counted as the time for the esophageal pH to recover to 4. The bolus or volume clearance can also be measured with the acid clearance by labeling the acid with radioactive material (usually technetium) and monitoring the radioactivity in the esophagus and esophageal pH simultaneously.
aTo whom all correspondence should be addressed: Richard W. McCallum Cholinergic stimulation is excitatory to esophageal peristalsis while nitrergic innervation is inhibitory. Experimental studies in cats, monkeys and humans demonstrate that atropine blockade reduces the amplitude of esophageal contractions and inhibits the progression of the peristaltic wave from the striated muscle to the smooth muscle. Atropine blockade has no effect on the propagation velocity in the smooth muscle itself. The inhibitory role of nitric oxide can be blocked by L-nitro-arginine-methyl-ester and nitric oxide scavengers, such as recombinant hemoglobin. Blockade of nitric oxide inhibition produces a dramatic increase in the propagation velocity of esophageal contractions. In the smooth muscle of the esophagus, nitric oxidemedicated inhibitory neurones mainly control the timing, and therefore the propagation velocity, of esophageal contractions, where as cholinergic excitatory neurones mainly determine the strength of the contraction.
In the case of GERD, a substantial number of patients have ineffective propagation of the peristaltic wave as well as reduced amplitude of the primary peristaltic wave. This decrease in amplitude corresponds directly to the severity of oesophagitis. In addition, patients with GERD have higher thresholds for induction of secondary peristalsis than patients without GERD.
In line with the pharmacological basis of esophageal peristalsis, cholinergic stimulation improves the disordered motility and clearance of patients with GERD. This stimulation can be produced either by bethanechol, which stimulates cholinergic receptors, or by cisapride and erythromycin, which act on receptors in the amplitude of esophageal contractions, a decrease in the propagation velocity of the peristaltic contractions, and an improvement in esophageal clearance and transit time. In both normal subjects and GERD patients, bethanechol increases the amplitude of peristalsis, decreases the progression velocity of peristalsis, and improves esophageal transit and clearance. Bethanechol's effect on propulsive force is unknown, although it does increase the amplitude of secondary esophageal peristaltic contraction.
Cisapride increases the amplitude and propagation velocity of peristalsis in normal patients and those with GERD. It accelerates the axial propagation and increases the overall contraction lengths of the peristaltic wave. However, it has not been found to reduce the rate of failed primary peristalsis in severe GERD patients. The clearance time of postprandial reflux in GERD is decreased by cisapride; however, the effect of cisapride on secondary esophageal peristalsis has not been studied extensively. Erythromycin does not affect the amplitude of peristalsis in normal patients or GERD patients, but does reduce the progression velocity and tends to improve peristaltic performance in GERD. The effects of erythromycin on propulsive force and secondary contractions are unknown.
All these motility drugs are less effective in severe cases of reflux esophagitis when nerves and/or muscles are diseased.
SPHINCTER MECHANISM AT GASTROESOPHAGEAL JUNCTION
The movement of gastric contents into the esophagus is prevented by the sphincteric mechanism at the gastroesophageal junction (GEJ), the major antireflux barrier. The intraluminal pressure at the GEJ determines the strength of this antireflux barrier. Recent studies indicate that the smooth muscles of the lower esophageal sphincter (LES) and skeletal muscles of the crural diaphragm contribute to the GEJ pressure. Because the LES and crural diaphragms are anatomically superimposed on each other, the intraluminal pressure measurement alone cannot distinguish between the contributions from the two structures. The evidence of the contribution of the crural diaphragm to the GEJ pressure requires simultaneous recordings of GEJ pressure and EMG of the crural diaphragm.
The pressure at the GEJ varies during inspiration and expiration. The end expiratory pressure is caused by the smooth muscles of the LES, and the inspiratory increase is caused by the active contraction of the crural diaphragm. This latter observation has been confirmed in animal studies as well as human studies. The increase in the GEJ pressure during inspiration is directly proportional to the force of inspiration, or in other words, the force of the crural diaphragm contraction. The LES and crural diaphragm reflexively contract to a number of other stimuli. Increases in intra-abdominal pressure, caused by either abdominal compression or straight-leg raises, cause reflex contractions of the crural diaphragm. The LES also reflexively contracts in response to increased intra-abdominal pressure. The LES pressure also is related to gastric motility and increases with its migrating motor complex (MMC) activity. The LES pressure is at its peak during phase 3 and lowest during phase 1 of the MMC activity. It is reasonable to assume that the increase in LES pressure during phase 3 of the MMC activity is required to counteract the increase in gastric pressure caused by gastric contraction.
GASTROESOPHAGEAL MOTOR EVENTS THAT FACILITATE GASTROESOPHAGEAL REFLUX
The ability to monitor LES pressure continuously using a Dent sleeve has greatly expanded our knowledge of the motor events associated with episodes of GER. Initial studies by Dent et The extent and duration of each of the pharmacological effects of cisapride depend on the experimental conditions under which they are studied. The main reasons for the discrepancies in findings are different methodologies and different selection criteria for the subjects investigated.
The reduction in esophageal exposure to acid, which allows symptomatic improvement and mucosal healing, is clearly a result of increased esophageal clearance due to the stimulation of esophageal peristalsis and salivary secretion as well as to the increase in sphincter resistance. Esophageal exposure to acid seems to depend on the gastric emptying rate and gastric emptying is often delayed in patients with GERD. In GERD patients with delayed gastric emptying, the pH is less than 4 for longer than in patients whose emptying rate is normal. In patients with gastric motor derangement, a significant correlation was found between the emptying half-life and the reflux time. Similarly, in a group of patients undergoing antireflux surgery, those with delayed gastric emptying had a significantly higher esophageal exposure to acid than did patients without gastric motor derangement.
Administration of cisapride before meals significantly accelerated gastric emptying of solids in both healthy individuals and patients with GERD. The postprandial esophageal exposure to acid was significant in the subgroup of patients with a delayed emptying rate. The same holds true for the duration of reflux episodes. Therefore, cisapride accelerates gastric emptying in reflux patients and strongly reduces esophageal exposure to acid. This last effect is particularly evident in patients with delayed gastric emptying, probably because of the ability of the drug to correct both esophageal and gastric motor disorders.
To summarize, the stimulation of both esophageal and gastric motility is an important determinant of cisapride efficacy in GERD. The improvement of esophageal clearance, the increase in sphincter resistance, and the acceleration in gastric emptying, with a consequent reduction in the gastric volume available for reflux, all contribute to the reduction of esophageal exposure to acid, which ultimately allows symptomatic relief and mucosal healing.
